In a nutshell This study investigated the occurrence of cachexia (CX; weight loss and muscle wasting) in patients with advanced colorectal cancer after first-line therapy. Researchers suggested that CX is present in half of these patients within 24 weeks after starting first-line therapy. Some background Colorectal cancer is the third most common...
Read More
In a nutshell This study compared the effectiveness of FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) with either cetuximab (Erbitux) or bevacizumab (Avastin) in the treatment of advanced colorectal cancer (CRC). Researchers suggested that FOLFIRI with cetuximab resulted in improved response and longer survival for these patients. Some...
Read More
In a nutshell This study investigated the effectiveness of treatment with irinotecan (Camptosar) combined with capecitabine (Xeloda) chemotherapy (ICC) before rectal cancer surgery. Researchers suggested that this combined therapy significantly improved the treatment outcomes in these patients. Some background Rectal cancer is a common...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This study investigated the long-term changes in sexual function (SF) in men after rectal cancer surgery. Researchers suggested that SF was not significantly affected by rectal cancer surgery. Some background Colorectal cancer is the third most common cancer worldwide. Of these, around 30% are rectal cancers. Newer cancer therapies...
Read More
In a nutshell This trial was carried out to examine the optimal time interval between completing chemoradiotherapy (CRT) and robotic-assisted surgery (RAS) in patients with rectal cancer. The trial found that RAS is safe and effective after 10-12 weeks of CRT. Some background Rectal cancer treatment has experienced an improvement with new...
Read More
In a nutshell This study investigated the long-term health-related quality of life (HQL) after colorectal cancer (CRC) surgery. Researchers suggested that overall long-term HQL was good, although some patients may need closer follow-up. Some background CRC is the third most common cancer worldwide. Surgery is the recommended treatment and is...
Read More
In a nutshell This study investigated whether chemotherapy plus bevacizumab (Avastin) before and after or after surgery improves the survival of patients with colorectal cancer (CRC) and operable liver metastasis (LM; cancer spread to the liver). Researchers suggested that chemotherapy and bevacizumab before and after...
Read More
In a nutshell This study investigated if vitamin D supplementation improves colorectal cancer (CRC) survival outcomes. Researchers suggested that vitamin D supplementation is associated with improved survival in CRC. Some background CRC is the third most common cancer diagnosed in both men and women in the US. It is more common in...
Read More
In a nutshell This study investigated Immunoscore (IMS) as a prognostic tool in patients with stage 3 colon cancer. Researchers suggested that a high IMS is associated with prolonged survival in these patients. Some background Colorectal cancer is the third most common cancer worldwide. A significant percentage of patients present with high-risk...
Read More
In a nutshell This study compared the effectiveness of three different treatments for metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that fruquintinib (Elunate) was associated with the best treatment outcomes. Some background Colorectal cancer is a common cancer worldwide and 25% of patients present with...
Read More
In a nutshell This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients. Some...
Read More
